medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2020, Número S1

<< Anterior Siguiente >>

Ginecol Obstet Mex 2020; 88 (S1)


Anticoncepción de emergencia en la práctica clínica

Durand-Carbajal MM

Idioma: Español
Referencias bibliográficas: 46
Paginas: 121-130
Archivo PDF: 200.52 Kb.


RESUMEN

La anticoncepción de emergencia, poscoito o píldora del día siguiente se refiere al consumo de ciertos anticonceptivos hormonales orales o la colocación de un dispositivo de cobre (DIU-TCu) posterior al coito como medida de emergencia para impedir un embarazo no deseado. La anticoncepción de emergencia es un método de respaldo ocasional y no para uso rutinario o continuo. La anticoncepción hormonal de emergencia, en cualquiera de sus presentaciones y compuestos, debe administrarse lo antes posible después del coito sin protección, en un plazo no mayor a 120 horas. Sin embargo, debe informársele a la mujer que la eficacia se reduce cuanto más se prolongue el intervalo entre el coito y la ingesta del anticonceptivo. La mayor eficacia se registra cuando se toma en las primeras 24 a 72 horas. No existen situaciones en que los riesgos de la anticoncepción de emergencia (en combinación o solo con progestina) superen las ventajas de la prevención del embarazo. Las mujeres con embarazo ectópico previo, que estén amamantando, con enfermedades cardiovasculares, migrañas y enfermedad hepática pueden recibir anticoncepción de emergencia. Es importante que el personal de salud prescriba correctamente los métodos anticonceptivos, incluida la anticoncepción de emergencia.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Grimes DA, et al. Unsafe abortion: the preventable pandemic. The Lancet Sexual and Reproductive Health Series. 2006. https://www.who.int/reproductivehealth/publications/ unsafe_abortion/lancet_paper/en/

  2. Ellertson C. History and efficacy of emergency contraception: beyond Coca-Cola. Fam Plann Perspect 1996;28:44-8.

  3. Parkes AS, et al. Studies on the internal secretions of the ovary. II. The effects of injection of the oestrus producing hormone during pregnancy. J Physiol 1926;62:145-55.

  4. Parkes AS, et al. Interruption of early pregnancy by orally active estrogens. Br Med J 1938;2:557-9. https://www.ncbi. nlm.nih.gov/pmc/articles/PMC2210500/

  5. Smith MG. On the interruption of pregnancy in the rat by the injection of ovarian follicular extract. Bull Johns Hopkins Hosp 1926;39:203-14.

  6. Morris JM, et al. Compounds interfering with ovum implantation and development. III. The role of estrogens. Am J Obstet Gynecol 1966;6:804-15.

  7. Yuzpe AA, et al. Post coital contraception: a pilot study. J Reprod Med 1974;13:53-61.

  8. World Health Organization. Task Force on Postovulatory Methods of Fertility Regulation. Randomized controlled trial of levonorgestrel versus the Yuzpe regimen of combined contraceptives for emergency contraception. Lancet 1998;352:428-33.

  9. Kovacs L, et al. Investigation of the pregnancy preventive effect of postcoital d-norgestrel under special experimental conditions. Honvedorvos 1979;3-4:289-93.

  10. Moggia A, et al. The use of progestogens as poscoital contraceptives. J Reprod Med 1974;13:58-61.

  11. Ho PC, et al. A prospective randomized comparison of levonorgestrel with the Yuzpe regimen in post-coital contraception. Hum Reprod 1993;8:389-92.

  12. Von Hertzen H, et al. Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomised trial. Lancet 2002;360:1803- 10. https://doi.org/10.1016/S0140-6736(02)11767-3

  13. Glasier A. Emergency postcoital contraception. N Engl J Med 1997;337:1058-64. https://doi.org/10.1056/ NEJM199710093371507

  14. Glasier AF, et al. Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysis. Lancet 2010;375:555-62. https:// doi.org/10.1016/S0140-6736(10)60101-8.

  15. World Health Organization. Special Programme of Research, Development and Research Trainig in Human Reproduction. Levonorgestrel for emergency contraception. Fact Sheet, October 2005. https://www.who.int/ life-course/partners/human-reproduction/en/

  16. Recomendaciones sobre prácticas seleccionadas para el uso de anticonceptivos, tercera edición en Español. Ginebra: Organización Mundial de la Salud; 2017. Licencia: CC BY-NC-SA 3.0 IGO. https://apps.who.int/iris/bitstream/ha ndle/10665/259814/9789243565408-spa.pdf?sequence=1

  17. Brache V, et al. Ulipristal acetate prevents ovulation more effectively than levonorgestrel: analysis of pooled data from three randomized trials of emergency contraception regimens. Contraception 2013;88:611-8. https://doi. org/10.1016/j.contraception.2013.05.010.

  18. Chirinos M, et al. Uterine flushings from women treated with levonorgestrel affect sperm functionality in vitro. Reproduction 2017;154:607-614. https://doi.org/10.1530/ REP-17-0313.

  19. Cleland K, et al. The efficacy of intrauterine devices for emergency contraception: systematic review of 35 years of experience. Hum Repro 2012;27:1994-2000. https:// doi.org/10.1093/humrep/des140.

  20. Kapp N, et al. Effect of body weight and BMI on the efficacy of levonorgestrel emergency contraception. Contraception 2015;91(2):97-104. https://doi.org/10.1016/j.contraception. 2014.11.001.

  21. European Medicines Agency. Levonorgestrel and ulipristal remain suitable emergency contraceptives for all women, regardless of bodyweight. http://www.ema.europa.eu/ema/ index.jsp?curl=pages/news_and_events/news/2014/07/ news_detail_002145.jsp&mid=WC0b01ac058004d5c1

  22. Croxatto HB, et al. Effects of the Yuzpe regimen, given during the follicular phase, on ovarian function. Contraception 2002;65:121-8.

  23. Durand M, et al. Mecanismos de acción de la anticoncepción hormonal de emergencia: efectos del levonorgestrel anteriores y posteriores a la fecundación. Salud Publica Mex 2009;51:255-261. https://scielosp.org/pdf/spm/2009. v51n3/255-261/es

  24. Durand M, et al. On the mechanisms of action of short-term levonorgestrel administration in emergency contraception. Contraception 2001;64:227-234.

  25. Trussell J, Raymond EG. Statistical evidence about the mechanism of action of the Yuzpe regimen of emergency contraception. Obstet Gynecol 1999;93:872-6.

  26. Durand M, et al. Late follicular phase administration of levonorgestrel as an emergency contraceptive changes the secretory pattern of glycodelin in serum and endometrium during the luteal phase of the menstrual cycle. Contraception 2005;71:451-457. https://doi.org/10.1016/j. contraception.2005.01.003

  27. Durand M, et al. Hormonal evaluation and midcycle detection of intrauterine glycodelin in women treated with levonorgestrel as in emergency contraception. Contraception 2010;82:526-33. https://doi.org/10.1016/j. contraception.2010.05.015

  28. Novikova N, et al. Effectiveness of levonorgestrel emergency contraception given before or after ovulation - a pilot study. Contraception 2006;74:349-50. https://doi. org/10.1016/j.contraception.2006.08.015

  29. Gemzell-Danielsson K, et al. Emergency contraception - mechanisms of action. Contraception 2013;87:300-8. https:// doi.org/10.1016/j.contraception.2013.04.007

  30. Brache V, et al. Immediate pre-ovulatory administration of 30 mg ulipristal acetate significantly delays follicular rupture. Hum Reprod 2010;25:2256-63. https://doi. org/10.1093/humrep/deq157.

  31. Li HW, et al. Efficacy of ulipristal acetate for emergency contraception and its effect on the subsequent bleeding pattern when administered before or after ovulation. Hum Reprod 2016;31:1200-07. https://doi.org/10.1093/humrep/dew055.

  32. Berger C, et al. Effects of ulipristal acetate on human embryo attachment and endometrial cell gene expression in an in vitro co-culture system. Hum Reprod 2015;30:800-11. https://doi.org/10.1093/humrep/dev030.

  33. Lira-Albarran S, et al. Ulipristal acetate administration at mid-cycle changes gene expression profiling of endometrial biopsies taken during the receptive period of the human menstrual cycle. Mol Cell Endocrinol 2017;447:1-11. https://doi.org/10.1016/j.mce.2017.02.024.

  34. Protection of Human Subjects. Title 45 Code of Federal Regulations. Part 46 (2009). https://www.hhs.gov/ohrp/sites/ default/files/ohrp/humansubjects/regbook2013.pdf.pdf

  35. Trussell J, et al. The effectiveness of postcoital hormonal contraception. Fam Plann Perspect 1992;24:262-4.

  36. WHO. Medical Eligibility Criteria for Contraceptive Use. Fifth edition, Ginebra, Suiza: World Health Organization, 2015. http://www.who.int/reproductivehealth/publications/ family_planning/MEC-5/en

  37. von Hertzen H, et al. Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomised trial. Lancet 2002;360:1803- 10. https://doi.org/10.1016/S0140-6736(02)11767-3

  38. Centers for Disease Control and Prevention. U S. Medical Eligibility Criteria for Contraceptive Use, 2010. MMWR 2010;59:1-85. https://www.cdc.gov/mmwr/preview/ mmwrhtml/rr5904a1.htm

  39. Raymond EG, et al. Bleeding patterns after use of levonorgestrel emergency contraceptive pills. Contraception 2006;73:376-81. https://doi.org/10.1016/j.contraception. 2005.10.006

  40. Zhang L, et al. Pregnancy outcome after levonorgestrelonly emergency contraception failure: a prospective cohort study. Hum Reprod 2009;24:1605-11. https://doi. org/10.1093/humrep/dep076.

  41. Polakow-Farkash S, et al. Levonorgestrel used for emergency contraception during lactation. A prospective observational cohort study on maternal and infant safety. J Matern Fetal Neonatal Med 2013;26:219-21. https://doi. org/10.3109/14767058.2012.722730.

  42. Faculty of Sexual and Reproductive Healthcare, Royal College of Obstetricians and Gynaecologists. Use of Ulipristal Acetate (ellaOne®) in Breastfeeding Women. Update from the Clinical Effectiveness Unit. Marzo de 2013. http:// pesimsr.pes.edu/obgyan/wp-content/uploads/2016/06/ UPAandBreastfeeding.pdf

  43. Guerts TB, et al. Summary of drug interactions with oral contraceptives. Carnforth, Inglaterra: Parthenon Publishing Group, Ltd., 1993. https://www.popline.org/node/333112

  44. Cameron ST, et al. The effects on ovarian activity of ulipristal acetate when 'quickstarting' a combined oral contraceptive pill: a prospective, randomized, double-blind parallel-arm, placebo-controlled study. Hum Reprod 2015;30:1566-72. https://doi.org/10.1093/humrep/dev115.

  45. Brache V, et al. A prospective, randomized pharmacodynamic study of quick-starting a desogestrel progestin-only pill following ulipristal acetate for emergency contraception. Hum Reprod 2015;30:2785-93. https://doi.org/10.1093/ humrep/dev241.

  46. Schiavon R, et al. Analysis of maternal and abortion-related mortality in Mexico over the last two decades, 1990-2008. Int J Gynaecol Obstet 2012;118(Suppl 2):S78-86. https:// doi.org/10.1016/S0020-7292(12)60004-6.




2020     |     www.medigraphic.com